Retatrutide's 28% figure — what is actually behind it?

The page gives 28.3% average weight reduction at 80 weeks on 12 mg, and 45.3% of participants losing at least 30% of body weight. Those are extraordinary numbers relative to everything else in the category.

Is that figure as solid as it reads? It is one of the very few compounds here with evidence: strong.

It is solid in the sense that matters: phase 3, published topline, a trial designed to answer the question it is being quoted for. That is a completely different evidentiary object from most of this site, and the strong label is earned.

The things to hold alongside it:

It is a mean. 28.3% average, with a distribution around it. Half the point of the 45.3%-lost-30% figure is that it tells you about the shape rather than just the centre — but it also means there are people at the other end.

80 weeks is 80 weeks. These are chronic-use drugs and the trial is not.

Trial populations are selected. Inclusion criteria, monitoring, adherence support. The effect in a trial is close to a ceiling for the effect in practice.

None of that is a debunk. It is a genuinely large effect, larger than anything approved. It is just a trial result rather than a promise.

Understood. What about the dysesthesia note on the page? That is unusual — I have not seen it on the other incretin compounds.

It is unusual, and it is on the page precisely because it is specific to this drug rather than a class effect.

Altered skin sensation, dose-related, affecting roughly one in eight participants at the higher doses against almost none on placebo. That separation from placebo is what makes it a real finding rather than background noise — in a trial that size, "one in eight versus almost none" is not the kind of thing that happens by chance.

It is not the GI business everybody expects from this class. It is its own thing, and it is the reason this compound has a safety note where a nearly identical-looking one might not.

Regulatory status is worth stating plainly since it gets glossed: this is not an approved medicine. The page notes a US filing planned for early 2027. Filed is not approved, and planned-to-file is not filed.

So the situation is: excellent trial evidence, no marketing authorisation anywhere, and therefore anything in circulation now is outside the framework entirely — with all the manufacturing questions that carries, and none of the answers that an approval would have brought with it.

Strong evidence for the molecule is not strong evidence for the vial.

"Strong evidence for the molecule is not strong evidence for the vial" is the sentence I was missing. That is the whole distinction.

It is also the distinction that the entire grey market for this class depends on people not making. The trial data does the persuading and the unapproved product collects.

Worth adding that the trial programme is broader than weight — the page mentions knee osteoarthritis pain and sleep apnoea outcomes. Those are secondary results and should be read as such, but they are the sort of thing that suggests the effect is doing real metabolic work rather than being a scale number.